All organisms growing beyond the oxygen diffusion limit critically depend on a functional
vasculature for survival. Yet blood vessels are far more than passive, uniform conduits for …

Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and
oxygen supply to the tumor cells through the decrease of the vascular network and the …

The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our
understanding of vasculogenesis and angiogenesis during development and physiological …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Tumours display considerable variation in the patterning and properties of angiogenic blood
vessels, as well as in their responses to anti-angiogenic therapy. Angiogenic programming …

The formation of new blood vessels, or angiogenesis, is a complex process that plays
important roles in growth and development, tissue and organ regeneration, as well as …

Tumor growth and metastasis rely on tumor vascular network for the adequate supply of
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …